Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.

Zheng CM, Wang JY, Chen TT, Wu YC, Wu YL, Lin HT, Chiu SP, Chang TJ, Zheng JQ, Chu NF, Lin YM, Su SL, Lu KC, Chen JS, Sung FC, Lee CT, Yang Y, Hwang SJ, Wang MC, Hsu YH, Chiou HY, Kao S, Wu MY, Lin YF.

Sci Rep. 2019 Feb 25;9(1):2694. doi: 10.1038/s41598-019-38991-z.

2.

Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.

Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.

JAMA Intern Med. 2014 Mar;174(3):347-54. doi: 10.1001/jamainternmed.2013.12700.

PMID:
24343093
3.

Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.

Wang PT, Huang YB, Lin MY, Chuang PF, Hwang SJ.

Kaohsiung J Med Sci. 2012 Sep;28(9):477-83. doi: 10.1016/j.kjms.2012.04.004. Epub 2012 Jul 7.

4.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
5.

Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.

Fröhlich H, Nelges C, Täger T, Schwenger V, Cebola R, Schnorbach J, Goode KM, Kazmi S, Katus HA, Cleland JG, Clark AL, Frankenstein L.

Am Heart J. 2016 Aug;178:28-36. doi: 10.1016/j.ahj.2016.03.024. Epub 2016 Apr 30.

6.

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.

Wu LS, Chang SH, Chang GJ, Liu JR, Chan YH, Lee HF, Wen MS, Chen WJ, Yeh YH, Kuo CT, See LC.

Cardiovasc Diabetol. 2016 Apr 2;15:56. doi: 10.1186/s12933-016-0365-x.

7.

Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.

Omae K, Ogawa T, Nitta K.

Heart Vessels. 2010 May;25(3):203-8. doi: 10.1007/s00380-009-1188-4. Epub 2010 May 29.

PMID:
20512447
8.

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, Cleland JG, Khwaja A, El Nahas M.

Nephrol Dial Transplant. 2016 Feb;31(2):255-61. doi: 10.1093/ndt/gfv346. Epub 2015 Sep 30.

9.

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.

Huang RS, Cheng YM, Zeng XX, Kim S, Fu P.

Chin Med J (Engl). 2016 Mar 5;129(5):562-9. doi: 10.4103/0366-6999.176987.

10.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.

Zhang L, Zeng X, Fu P, Wu HM.

Cochrane Database Syst Rev. 2014 Jun 23;(6):CD009120. doi: 10.1002/14651858.CD009120.pub2. Review.

PMID:
24953826
11.

Aldosterone antagonists for preventing the progression of chronic kidney disease.

Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.

Cochrane Database Syst Rev. 2014 Apr 29;(4):CD007004. doi: 10.1002/14651858.CD007004.pub3. Review.

PMID:
24782282
12.

Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP.

J Am Coll Cardiol. 2014 Feb 25;63(7):650-658. doi: 10.1016/j.jacc.2013.10.050. Epub 2013 Nov 21.

13.

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.

Shen JI, Saxena AB, Vangala S, Dhaliwal SK, Winkelmayer WC.

BMC Nephrol. 2017 Jun 17;18(1):196. doi: 10.1186/s12882-017-0616-4.

14.

Aldosterone antagonists for preventing the progression of chronic kidney disease.

Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007004. doi: 10.1002/14651858.CD007004.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD007004.

PMID:
19588415
15.

Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.

Noh Y, Lee J, Shin S, Park I, Bae SK, Oh E, Lee S.

Int J Clin Pharm. 2018 Feb;40(1):160-168. doi: 10.1007/s11096-017-0578-4. Epub 2017 Dec 27.

PMID:
29282632
16.

Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.

Shah M, Jain AK, Brunelli SM, Coca SG, Devereaux PJ, James MT, Luo J, Molnar AO, Mrkobrada M, Pannu N, Parikh CR, Paterson M, Shariff S, Wald R, Walsh M, Whitlock R, Wijeysundera DN, Garg AX.

BMC Nephrol. 2014 Apr 2;15:53. doi: 10.1186/1471-2369-15-53.

17.

Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.

Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.

Clin Exp Nephrol. 2011 Oct;15(5):700-707. doi: 10.1007/s10157-011-0455-8. Epub 2011 May 31.

PMID:
21625892
18.

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.

Evans M, Carrero JJ, Szummer K, Åkerblom A, Edfors R, Spaak J, Jacobson SH, Andell P, Lindhagen L, Jernberg T.

J Am Coll Cardiol. 2016 Apr 12;67(14):1687-97. doi: 10.1016/j.jacc.2016.01.050.

19.

Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.

Wu CK, Yang YH, Juang JM, Wang YC, Tsai CT, Lai LP, Hwang JJ, Chiang FT, Chen PC, Lin JL, Lin LY.

Medicine (Baltimore). 2015 Jan;94(3):e424. doi: 10.1097/MD.0000000000000424.

20.

Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?

Brooks JM, Chapman CG, Suneja M, Schroeder MC, Fravel MA, Schneider KM, Wilwert J, Li YJ, Chrischilles EA, Brenton DW, Brenton M, Robinson J.

J Am Heart Assoc. 2018 May 30;7(11). pii: e009137. doi: 10.1161/JAHA.118.009137.

Supplemental Content

Support Center